Dendreon reports survival data on Provenge

02/14/2008 | Forbes

The overall survival of prostate cancer patients taking Dendreon's experimental vaccine Provenge appears to improve when they receive more potent doses of the drug, according to data the company released Thursday. Dendreon is trying to get FDA approval for the vaccine.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ